We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Autologous Bone Marrow Mononuclear Cells in Liver Cirrhosis (CELTHEP-02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00832247
Recruitment Status : Unknown
Verified January 2009 by Universidade Federal do Rio de Janeiro.
Recruitment status was:  Recruiting
First Posted : January 30, 2009
Last Update Posted : January 30, 2009
Information provided by:

January 29, 2009
January 30, 2009
January 30, 2009
January 2009
April 2010   (Final data collection date for primary outcome measure)
Liver function worsening [ Time Frame: One year ]
Same as current
No Changes Posted
  • Liver related mortality [ Time Frame: One year ]
  • Hepatocellular carcinoma development accessed by ultrasound and CT scan [ Time Frame: One year ]
  • BMMC kinetics accessed by total body scintigraphy [ Time Frame: 24 hours ]
  • Liver tissue changes evaluated by histopathology analysis and molecular biology [ Time Frame: 10 weeks ]
Same as current
Not Provided
Not Provided
Autologous Bone Marrow Mononuclear Cells in Liver Cirrhosis
Phase 1 Study of Autologous Bone Marrow Mononuclear Cells Infusion in Peripheral Vein in Liver Cirrhosis Due to Hepatitis C Virus

This is a phase I clinical study to evaluate feasibility, safety and kinetics of cellular therapy with autologous bone marrow-derived mononuclear cells (BMMC) in patients with liver cirrhosis due to virus C hepatitis. Another aim is to study liver tissue changes induced by the BMMC presence. All the patients have moderate liver disfunction and will be submitted to a liver biopsy before BMMC injection. The cells will be labeled with 99mTc and infused through a peripheral vein. Scintigraphy will be performed 24 hours after infusion.

Patients will be submitted to frequent clinical, laboratorial and image evaluation during a one-year follow-up. A second liver biopsy will be done in the 3rd month after infusion to check histological, cellular and molecular evolutive changes.

Not Provided
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Liver Cirrhosis Due to Virus C Chronic Hepatitis
Genetic: Autologous bone marrow mononuclear cells infusion
At least 100.000.000 autologous BMMC will be infused in a peripheral vein once suspended in albumine during 10 minutes
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
April 2010
April 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Chronic virus C hepatitis
  • Liver cirrhosis
  • Moderate liver disfunction

Exclusion Criteria:

  • Malignant disease
  • Pregnancy
  • Significant comorbidity
  • Portal vein thrombosis
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Guilherme Ferreira da Motta Rezende, Federal UNiversity of Rio de Janeiro
Universidade Federal do Rio de Janeiro
  • Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
  • Financiadora de Estudos e Projetos
  • Oswaldo Cruz Foundation
  • University of Edinburgh
Principal Investigator: Guilherme FM Rezende, MD PhD Universidade Federal do Rio de Janeiro
Universidade Federal do Rio de Janeiro
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP